Ponatinib for chronic myeloid leukemia.

  title={Ponatinib for chronic myeloid leukemia.},
  author={John M. Goldman},
  journal={The New England journal of medicine},
  volume={367 22},
The treatment of patients with chronic myeloid leukemia (CML) must be ranked as one of the great medical success stories of the past 30 years. The demonstration that the Philadelphia (Ph) chromosome carries a fusion gene formed by the juxtaposition of BCR and ABL genetic sequences focused attention on the possibility that the tyrosine kinase activity of ABL might be greatly enhanced by fusion with BCR such that the BCR-ABL oncoprotein could be the primary cause of CML. If it were so, then… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 13 times over the past 90 days. VIEW TWEETS
11 Citations
8 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 11 extracted citations


Publications referenced by this paper.
Showing 1-8 of 8 references

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

  • BJ Druker, S Tamura, E Buchduner
  • Nat Med
  • 1996

PACE : a pivotal phase 2 trial of ponatinib in patients with CML and Ph + ALL resistant or intolerant to dasatinib or nilotinib , or with the T 315 mutation

  • JM Gozgit, S Wardwell

Similar Papers

Loading similar papers…